Selpercatinib: First Approval

Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA f...

Descripción completa

Detalles Bibliográficos
Autor principal: Markham, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
AdisInsight Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716849/
https://www.ncbi.nlm.nih.gov/pubmed/32557397
http://dx.doi.org/10.1007/s40265-020-01343-7
_version_ 1783619239159005184
author Markham, Anthony
author_facet Markham, Anthony
author_sort Markham, Anthony
collection PubMed
description Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. This article summarizes the milestones in the development of selpercatinib leading to this first approval.
format Online
Article
Text
id pubmed-7716849
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-77168492020-12-04 Selpercatinib: First Approval Markham, Anthony Drugs AdisInsight Report Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA for the treatment of RET fusion-positive non-small-cell lung cancer, RET fusion-positive thyroid cancer and RET-mutant medullary thyroid cancer. This article summarizes the milestones in the development of selpercatinib leading to this first approval. Springer International Publishing 2020-12-30 2020 /pmc/articles/PMC7716849/ /pubmed/32557397 http://dx.doi.org/10.1007/s40265-020-01343-7 Text en © Springer Nature 2020, corrected publication 2020 Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle AdisInsight Report
Markham, Anthony
Selpercatinib: First Approval
title Selpercatinib: First Approval
title_full Selpercatinib: First Approval
title_fullStr Selpercatinib: First Approval
title_full_unstemmed Selpercatinib: First Approval
title_short Selpercatinib: First Approval
title_sort selpercatinib: first approval
topic AdisInsight Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716849/
https://www.ncbi.nlm.nih.gov/pubmed/32557397
http://dx.doi.org/10.1007/s40265-020-01343-7
work_keys_str_mv AT markhamanthony selpercatinibfirstapproval

Ejemplares similares